D H Harpole Jr
Overview
Explore the profile of D H Harpole Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DAmico T, Aloia T, Moore M, Conlon D, Herndon 2nd J, Kinch M, et al.
Ann Thorac Surg
. 2001 Oct;
72(4):1144-8.
PMID: 11603427
Background: The use of molecular markers in staging non-small cell lung cancer (NSCLC) has been supported in retrospective prognostic models but has not been evaluated in predicting sites of metastases....
2.
Aloia T, Harpole Jr D, Reed C, Allegra C, Moore M, Herndon 2nd J, et al.
Ann Thorac Surg
. 2001 Sep;
72(3):859-66.
PMID: 11565671
Background: This study was designed to determine the prognostic value of immunohistochemical tumor marker expression in a population of patients with node-negative esophageal cancer treated with complete resection alone. Methods:...
3.
Marom E, Aloia T, Moore M, Hara M, Herndon 2nd J, Harpole Jr D, et al.
Lung Cancer
. 2001 Sep;
33(2-3):99-107.
PMID: 11551404
Purpose: To correlate FDG activity on PET with the expression of glucose transporter proteins Glut-1 and Glut-3 in patients with early stage non-small cell lung cancer (NSCLC). Methods: Over a...
4.
Harpole Jr D, Moore M, Herndon 2nd J, Aloia T, DAmico T, Sporn T, et al.
Clin Cancer Res
. 2001 Apr;
7(3):562-9.
PMID: 11297249
The purpose of this study was to define the prognostic value of a group of molecular tumor markers in a well-staged population of patients treated with trimodality therapy for esophageal...
5.
Lau C, Harpole Jr D, Patz E
Chest Surg Clin N Am
. 2000 Nov;
10(4):781-801.
PMID: 11091926
In summary, noninvasive clinical staging techniques aid in stratifying patients into similar prognostic and therapeutic categories. Every patient with presumed non-small cell lung cancer should undergo a thorough history and...
6.
DAmico T, Harpole Jr D
Chest Surg Clin N Am
. 2000 Sep;
10(3):451-69.
PMID: 10967750
Several mechanisms of resistance to chemotherapy have been identified among the agents that are commonly used in the systemic treatment of patients with esophageal cancer: paclitaxel, platinum, and 5-FU. A...
7.
Patz Jr E, Rossi S, Harpole Jr D, Herndon J, Goodman P
Chest
. 2000 Jun;
117(6):1568-71.
PMID: 10858384
Objective: The purpose of this study was to determine the relationship between tumor size and survival in patients with stage IA non-small cell lung cancer (non-small cell lung cancer; ie,...
8.
DAmico T, Aloia T, Moore M, Herndon 2nd J, Brooks K, Lau C, et al.
Ann Thorac Surg
. 2000 Apr;
69(3):882-6.
PMID: 10750777
Background: This study is designed to assess molecular biologic substaging according to gender and histology in patients with stage I non-small cell lung cancer (NSCLC). Methods: Pathologic specimens were collected...
9.
Lau C, Harpole Jr D
Semin Surg Oncol
. 2000 Feb;
18(2):116-23.
PMID: 10657913
Clinical staging of lung cancer helps to determine the extent of disease and stratify patients into similar therapeutic and prognostic categories. A primary goal of clinical staging is to separate...
10.
Grichnik K, Ijsselmuiden A, DAmico T, Harpole Jr D, White W, Blumenthal J, et al.
Ann Thorac Surg
. 1999 Dec;
68(5):1786-91.
PMID: 10585059
Background: Cardiac operations frequently are complicated by postoperative cognitive decline. Less common and less studied is postoperative cognitive decline after noncardiac surgery, so we determined its incidence, severity, and possible...